Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICON plc filings document current-report disclosures for a foreign private issuer in the clinical research organization sector. Form 6-K reports furnish press releases and exhibits on operating results, financial guidance, earnings-call scheduling, conference presentations, shareholder voting matters, governance updates, and clinical or regulatory disclosures.
The filings also record accounting-practices and internal-control matters, including revenue-recognition disclosures, as well as XBRL financial information covering operating results, equity accounts and reporting-segment data. These documents frame ICON’s public-company reporting around clinical development services, capital structure, governance and risk-related material events.
ICON plc (ICLR) reported on its 2025 ICON Cares ESG progress, highlighting advances in environmental performance, patient impact, innovation and workforce initiatives. ICON achieved an EcoVadis score of 87/100, earning Platinum status and placing it in the top 1% of assessed organisations, and improved its CDP Climate Change score from B- to B. Environmental actions included sourcing 97.05% of global electricity from renewable sources in 2025, a 24% reduction in electricity use versus a 2018 baseline, and a 73.56% reduction in Scope 1 and 2 greenhouse gas emissions versus 2019, along with a 6.74% reduction in Scope 3 emissions versus 2022. ICON supported over 1,370 clinical studies involving more than 411,400 patients in 2025, contributing to 25 unique products receiving original or supplemental approval. The company employed approximately 40,200 people in 99 locations across 55 countries as of June 30, 2026.
ICON plc, through wholly owned subsidiary ICON Investments Six Designated Activity Company, issued $2.15 billion of senior unsecured notes in three tranches: $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031, and $650 million of 5.995% notes due 2036. The notes are guaranteed on a senior unsecured basis by ICON and were sold in a private placement to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
ICON applied the net proceeds to repay all outstanding term loans under its senior secured term loan facility, redeem in full its 5.809% senior secured notes due 2027, and repay all borrowings under a bridge facility. Following repayment of the bridge facility and term loans, collateral securing ICON’s revolving credit facility and existing notes, and related subsidiary guarantees, were automatically released. ICON also entered into a registration rights agreement to conduct an exchange offer so that, subject to conditions, the notes can be exchanged for registered notes with similar terms by November 11, 2027.
Invesco Ltd., a Bermuda-based parent holding company, filed an amended Schedule 13G reporting beneficial ownership of ICON PLC common stock. Invesco, through its investment adviser subsidiaries, may be deemed to beneficially own 5,264,236 shares, representing 6.9% of the outstanding common stock. It has sole voting power over 5,198,110 shares and sole dispositive power over 5,264,236 shares, with no shared voting or dispositive power. The shares are held of record by Invesco’s clients, none of whom individually has more than 5% economic ownership, and those clients are entitled to dividends and sale proceeds.
ICON plc director Anne Clem Whitaker reported equity compensation activity around vesting of restricted share units. On August 10, 2026, 1,732 restricted share units vested and were converted into the same number of ordinary shares, with a nominal conversion price of EUR 0.06 per share deducted from pay. She also received a new grant of 1,324 restricted share units scheduled to vest on May 22, 2027. On August 11, 2026, 841 ordinary shares were sold in multiple trades at weighted-average prices around $162.72–$165.51 solely to cover tax withholding obligations under a "sell to cover" arrangement, which the filing states did not represent a discretionary transaction.
ICON plc director Julie O’Neill reported equity award activity and related tax sales. On August 10, 2026, 1,732 restricted share units vested into 1,732 ordinary shares and 1,324 new restricted share units were granted, each RSU representing one ordinary share with a nominal conversion price equal to EUR 0.06 per share deducted from pay. On August 11, 2026, a total of 915 ordinary shares were sold in multiple transactions to cover tax withholding obligations via a "sell to cover" arrangement, which the company states does not represent discretionary transactions by the reporting person.
ICON plc director Ciaran Murray reported a vesting-related share transaction. On August 10, 2026, 2,677 previously granted restricted share units vested, each converting into one ordinary share at a nominal conversion price equal to the EUR 0.06 par value, deducted from his pay. On August 11, 2026, he sold all 2,677 vested ordinary shares in multiple open-market trades at weighted-average prices within ranges from $162.08 to $166.1599, including shares sold to cover tax withholding obligations. He also received a new award of 2,047 restricted share units on August 10, 2026, scheduled to vest on May 22, 2027.
ICON PLC director Ronan Martin Murphy reported multiple equity transactions. On August 10, 2026, 1,732 restricted share units vested, converting into the same number of ordinary shares, with a nominal EUR 0.06 per-share amount deducted from pay. He also received a new grant of 1,324 restricted share units scheduled to vest on May 22, 2027. On August 11, 2026, he sold 841 ordinary shares in several open-market trades at weighted-average prices around $162–$166, solely to cover tax withholding obligations in a non-discretionary "sell to cover" transaction.
ICON PLC director Eugene Pacelli McCague reported multiple equity transactions. On August 10, 2026, 1,732 restricted share units granted on May 22, 2025 vested, converting into 1,732 ordinary shares with a nominal conversion price equal to the EUR 0.06 par value per share deducted from pay. On the same date he received a new grant of 1,324 restricted share units scheduled to vest on May 22, 2027.
On August 11, 2026, he sold an aggregate of 841 ordinary shares in several tranches at weighted-average prices between $162.08 and $166.1599 per share. According to the footnotes, these sales were solely to cover tax withholding obligations via a “sell to cover” arrangement and did not represent discretionary trading decisions.
ICON PLC reported that Chief Accounting Officer Emer Lyons received a grant of 5,886 Restricted Share Units on August 10, 2026. Each RSU represents a contingent right to receive one ordinary share upon vesting, with a nominal conversion price equal to the ordinary share par value of EUR 0.06 per share automatically deducted from pay at vesting. The RSUs are scheduled to vest in three approximately equal installments on May 22, 2027, May 22, 2028, and May 22, 2029, and Lyons’ directly held RSU balance after this grant is 5,886 units.